The U.S. continues to be a pivotal market for the Varicella Zoster Infection Industry, driven by a high incidence of herpes infections among children and a notable rise in pet-related disorders. The Centers for Disease Control estimates one million herpes zoster cases annually, with approximately 4 cases per 1,000 population. Major industry players further bolster growth in this region.
Germany stands out as a lucrative market in Western Europe, boasting a 24.7% market share in 2021. This dominance is expected to persist due to the region’s higher herpes prevalence and increased research and development activities. Incidence rates for HZ are notably high among individuals aged 50 and older.
Japan emerges as a growing market for Varicella zoster infection treatment, holding a 6.9% global market share in 2021. This growth is attributed to the rising incidence of Herpes Zoster among individuals aged 50 or older. Government funding and support for vaccination and awareness campaigns are expected to further drive market expansion.
In China, the Varicella Zoster Infection Treatment Market is on the rise, with an 8.7% share in the global market in 2021 and a projected CAGR of 4.5% from 2022 to 2028. This growth is primarily due to the increasing risk of herpes zoster among the aging population, where 32% of the population is aged 50 years and older. As the elderly population continues to grow, the burden of shingles is expected to rise in China.
Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-6466
Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.
In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.
Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market
Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.
These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment industry.
Grab Your Discount Now before It is Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-6466
Natural Products to Challenge Market Growth
Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.
Key Players:
- Novartis AG,
- Pfizer Inc.,
- Abbott Laboratories,
- Sun Pharmaceuticals Industries Ltd.,
- Valeant Pharmaceuticals International Inc.,
- Teva Pharmaceutical Industries Ltd.,
- Dr. Reddy’s Laboratories, ltd.,
- Mylan N.V. and
- GlaxoSmithKline
Varicella Zoster Infection Treatment – Market Segmentation – by Category
By Drug Type:
- Acyclovir
- Valacyclovir
- Famciclovir
Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-6466
By Route of Administration:
- Oral
- Injectable
- Topical
By Distribution Channel:
- Hospital pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
